IL-33 treatment accelerated enterocolitis in the IL-10−/− mice, but similarly treated WT C57BL/6 mice were essentially protected from the IL-33-mediated mucosal inflammatory disease (Fig. 1). Here, IL33 is linked to enterocolitis.